Has Glenmark Pharma declared dividend?

Yes, Glenmark Pharmaceuticals has declared a 250% dividend, amounting to ₹2.5 per share, with an ex-date of September 13, 2024. The company has shown strong total returns over various periods, particularly in the long term.

Glenmark Pharmaceuticals Ltd. has declared a 250% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 250%<BR>- Amount per share: 2.5<BR>- Ex-date: 13 Sep 24<BR><BR>Dividend Yield: 0.16%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 3.97%, with no dividend return, resulting in a total return of 3.97%.<BR><BR>Over the past year, the price return was 31.68%, with a dividend return of 0.21%, leading to a total return of 31.89%.<BR><BR>In the 2-year period, the price return was 152.58%, with a dividend return of 0.78%, culminating in a total return of 153.36%.<BR><BR>For the 3-year period, the price return was 305.84%, with a dividend return of 2.04%, resulting in a total return of 307.88%.<BR><BR>In the last 4 years, the price return was 159.41%, with a dividend return of 1.50%, giving a total return of 160.91%.<BR><BR>Over the 5-year period, the price return was 295.81%, with a dividend return of 2.87%, leading to a total return of 298.68%.<BR><BR>Overall, Glenmark Pharma has declared a substantial dividend, and the total returns over various periods indicate strong price appreciation, particularly over the longer term, suggesting a positive performance trend for the company.

Who are the peers of the Glenmark Pharma?

Glenmark Pharma's peers include Dr Reddy's Labs, Zydus Lifesci., Lupin, Abbott India, Aurobindo Pharma, Alkem Lab, Glaxosmi. Pharma, Biocon, and Laurus Labs. Glenmark has an average management risk and a 1-year return of 56.34%, outperforming Zydus Lifesci. but lower than Laurus Labs' 76.44%.

Peers: Glenmark Pharma's peers are Dr Reddy's Labs, Zydus Lifesci., Lupin, Abbott India, Aurobindo Pharma, Alkem Lab, Glaxosmi. Pharma, Biocon, Laurus Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Reddy's Labs, Abbott India, and Glaxosmi. Pharma, while Good management risk is found at Zydus Lifesci., Aurobindo Pharma, Alkem Lab, and Laurus Labs. Average management risk is present at Lupin, Glenmark Pharma, and Biocon. In terms of Growth, Excellent growth is seen at Dr Reddy's Labs and Zydus Lifesci., while Average growth is noted at Abbott India and Laurus Labs, and Below Average growth is found at Aurobindo Pharma, Glenmark Pharma, Alkem Lab, Glaxosmi. Pharma, and Biocon. For Capital Structure, Excellent capital structure is observed at Dr Reddy's Labs, Zydus Lifesci., Abbott India, Aurobindo Pharma, and Glaxosmi. Pharma, while Good capital structure is present at Glenmark Pharma, and Average capital structure is seen at Laurus Labs and Biocon.<BR><BR>Return Snapshot: Glenmark Pharma has a 1-year return of 56.34%, while the highest return is from Laurus Labs at 76.44% and the lowest is from Zydus Lifesci. at -18.37%. Glenmark Pharma's return is significantly higher than Zydus Lifesci.'s. Additionally, Aurobindo Pharma and Alkem Lab have negative six-month returns.

Who are in the management team of Glenmark Pharma?

As of March 2023, Glenmark Pharma's management team includes Glenn Saldanha (Chairman/Executive Director), Cheryl Pinto (Executive Director), and several independent directors, totaling a diverse group focused on governance and strategic direction.

As of March 2023, the management team of Glenmark Pharma includes:<BR><BR>1. Glenn Saldanha - Chairman / Executive Director<BR>2. Cheryl Pinto - Executive Director (Corporate)<BR>3. V S Mani - Executive Director & Group CFO<BR>4. B E Saldanha - Non Executive Director<BR>5. Rajesh Desai - Independent Non Executive Director<BR>6. Devendra Raj Mehta - Independent Non Executive Director<BR>7. Bernard Munos - Independent Non Executive Director<BR>8. Brian W Tempest - Independent Non Executive Director<BR>9. Sridhar Gorthi - Independent Non Executive Director<BR>10. Sona Saira Ramasastry - Independent Non Executive Director<BR>11. Dipankar Bhattacharjee - Independent Non Executive Director<BR>12. V R Iyer - Independent Non Executive Director<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and strategic direction of the company.

What does Glenmark Pharma do?

Glenmark Pharmaceuticals Ltd. is a large-cap company engaged in the discovery, development, manufacture, and marketing of pharmaceutical products. As of March 2025, it reported net sales of ₹32,562 Cr and a net profit of ₹46 Cr, with a market cap of ₹62,822 Cr.

Overview: <BR>Glenmark Pharmaceuticals Ltd. is a large-cap company in the Pharmaceuticals & Biotechnology industry, focused on the discovery, development, manufacture, and marketing of pharmaceutical products, including both formulations and active pharmaceutical ingredients.<BR><BR>History: <BR>Glenmark Pharmaceuticals Ltd. was incorporated on November 18th, 1977. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 32,562 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 46 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 62,822 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 50.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.11% <BR>Debt Equity: 0.09 <BR>Return on Equity: 14.15% <BR>Price to Book: 7.11<BR><BR>Contact Details: <BR>Address: B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road Mumbai Maharashtra : 400026 <BR>Tel: 91-22-40189999 <BR>Email: complianceofficer@glenmarkpharma.co <BR>Website: http://www.glenmarkpharma.com

Who are the top shareholders of the Glenmark Pharma?

The top shareholders of Glenmark Pharma include the Saldanha Family Trust with 45.45%, institutional investors holding 36.02% (including 25 mutual fund schemes at 12.86% and 347 FIIs at 23.16%), and individual investors with 12.32%. HDFC Mutual Fund is the largest public shareholder with a 4.27% stake.

The top shareholders of Glenmark Pharma include the Saldanha Family Trust, which holds the largest stake at 45.45%. The company also has significant institutional backing, with 25 mutual fund schemes collectively holding 12.86% and 347 foreign institutional investors (FIIs) holding 23.16%. Additionally, HDFC Mutual Fund, specifically through the HDFC Nifty Large Midcap 250 Index fund, is the highest public shareholder with a 4.27% stake. Individual investors collectively own 12.32% of the company.

How big is Glenmark Pharma?

As of 24th July, Glenmark Pharmaceuticals Ltd. has a market capitalization of 60,195.00 Cr, with recent net sales of 13,321.73 Cr and a net profit of 1,047.09 Cr.

As of 24th July, Glenmark Pharmaceuticals Ltd. has a market capitalization of 60,195.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Glenmark Pharmaceuticals reported Net Sales of 13,321.73 Cr and a Net Profit of 1,047.09 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 7,847.93 Cr and Total Assets of 13,308.90 Cr.

Are Glenmark Pharma latest results good or bad?

Glenmark Pharmaceuticals' latest results show a significant 34.3% decline in Profit After Tax, despite a slight 0.25% increase in net sales. Overall, the financial outlook is concerning, leading to a 'Hold' recommendation for the stock.

Glenmark Pharmaceuticals' latest financial results indicate a challenging situation for the company. For the quarter ending June 2025, the Profit After Tax (PAT) declined significantly by 34.3% compared to the average PAT of the previous four quarters, standing at Rs 205.71 crore. Additionally, the Profit Before Tax (PBT) also decreased by 5.4%, highlighting ongoing difficulties in maintaining profitability.<BR><BR>On a positive note, there was a slight increase in net sales, with a growth of 0.25% compared to the previous quarter, which suggests some stabilization in revenue. However, the increase in interest expenses by nearly 24% over the last six months raises concerns about the company's financial stability moving forward.<BR><BR>Overall, while there are some signs of improvement in sales, the substantial drop in profitability and rising costs indicate that the results are more concerning than positive. The stock call remains a 'Hold', reflecting a cautious outlook on the company's performance.

Is Glenmark Pharma technically bullish or bearish?

As of September 10, 2025, Glenmark Pharma's trend is mildly bullish, supported by daily moving averages and weekly Bollinger Bands, but tempered by mixed signals from the MACD and OBV.

As of 10 September 2025, the technical trend for Glenmark Pharma has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating bullish momentum and the weekly Bollinger Bands also showing bullish signals. However, the weekly MACD is mildly bearish and the KST is bullish on a weekly basis but mildly bearish on a monthly basis, suggesting some mixed signals. The Dow Theory indicates a mildly bullish stance on the weekly chart, while the OBV shows a mildly bearish trend. Overall, the strength of the bullish sentiment is tempered by the mixed indicators, particularly on the weekly timeframe.

When is the next results date for Glenmark Pharma?

Glenmark Pharma will announce its results on 14 November 2025.

Glenmark Pharma will declare its results on 14 November 2025.

How has been the historical performance of Glenmark Pharma?

Glenmark Pharma's historical performance shows significant fluctuations, with net sales increasing to 13,321.74 Cr in Mar'25 after a dip in Mar'23, and a recovery in profit after tax to 1,047.14 Cr in Mar'25 from a loss of 1,830.85 Cr in the previous year. Despite negative cash flow from operating activities in Mar'25, the company demonstrates a recovery trajectory following a challenging period.

Answer:<BR>The historical performance of Glenmark Pharma shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Glenmark Pharma's net sales increased from 10,640.97 Cr in Mar'20 to 13,321.74 Cr in Mar'25, with a notable dip in Mar'23 at 12,990.11 Cr. Total operating income followed a similar trend, reaching 13,321.74 Cr in Mar'25. The total expenditure, excluding depreciation, rose from 8,279.66 Cr in Mar'19 to 10,970.36 Cr in Mar'25. Operating profit (PBDIT) saw fluctuations, peaking at 2,595.16 Cr in Mar'23 before declining to 2,465.10 Cr in Mar'25. Profit before tax was 1,399.21 Cr in Mar'25, recovering from a low of 36.50 Cr in Mar'24. The profit after tax turned positive at 1,047.14 Cr in Mar'25 after a significant loss of 1,830.85 Cr in the previous year. The earnings per share (EPS) rebounded to 37.1 in Mar'25 from a negative EPS of -53.21 in Mar'24. Total assets increased to 14,925.44 Cr in Mar'25, while total liabilities also rose to 14,925.44 Cr, indicating a balanced growth in the company’s financial structure. Cash flow from operating activities was negative at -827.00 Cr in Mar'25, contrasting with a positive cash flow of 782.00 Cr in Mar'24. Overall, Glenmark Pharma's financial performance reflects a recovery trajectory in 2025 after a challenging previous year.

Should I buy, sell or hold Glenmark Pharma?

Is Glenmark Pharma overvalued or undervalued?

As of November 17, 2025, Glenmark Pharma is considered undervalued with a PE ratio of 23.47 and strong growth potential, outperforming peers like Sun Pharma and Cipla, and has delivered a 21.44% return over the past year compared to the Sensex's 9.50%.

As of 17 November 2025, Glenmark Pharma's valuation grade has moved from expensive to attractive, indicating a shift in market perception. The company is currently considered undervalued. Key ratios supporting this assessment include a PE ratio of 23.47, an EV to EBITDA of 12.50, and a PEG ratio of 0.04, which suggests strong growth potential relative to its price.<BR><BR>In comparison to its peers, Glenmark Pharma's valuation metrics stand out; for instance, Sun Pharma has a significantly higher PE ratio of 36.69, while Cipla, another attractive peer, has a PE of 22.81. This positions Glenmark favorably within the industry, particularly given its robust ROCE of 44.14% and ROE of 23.46%. Additionally, Glenmark's stock has outperformed the Sensex over the past year, with a return of 21.44% compared to the Sensex's 9.50%, reinforcing the attractiveness of its current valuation.

Which are the latest news on Glenmark Pharma?

Why is Glenmark Pharma falling/rising?

As of 04-Dec, Glenmark Pharmaceuticals Ltd. is seeing a stock price increase to 1,977.00, driven by strong financial performance, attractive valuation, and heightened investor interest. The company has outperformed benchmarks significantly, with a year-to-date return of 22.88% and impressive profit growth, indicating robust investor confidence.

As of 04-Dec, Glenmark Pharmaceuticals Ltd. is experiencing a rise in its stock price, currently at 1,977.00, reflecting an increase of 11.1 (0.56%). This upward movement can be attributed to several positive factors highlighted in the data. <BR><BR>Firstly, the stock has shown strong performance relative to the benchmark, outperforming the Sensex by 1.75% over the past week and 7.06% over the past month. Year-to-date, Glenmark has delivered a remarkable return of 22.88%, significantly higher than the Sensex's 9.12%. Over the past year, the stock has increased by 27.86%, while the benchmark has only gained 5.32%. Such consistent outperformance indicates strong investor confidence.<BR><BR>Additionally, the company has reported outstanding financial results, including a staggering 1199.62% growth in net profit as of September 25. This impressive performance is supported by a high return on capital employed (ROCE) of 35.65% and a robust operating profit to interest ratio of 35.50 times. The company's liquidity position is also strong, with cash and cash equivalents at Rs 2,690.24 crore.<BR><BR>The stock's valuation appears attractive, trading at a price-to-book value of 5.8, which is a discount compared to its peers. Furthermore, the company has a low debt-to-EBITDA ratio of 0.89 times, indicating a strong ability to service its debt, which is a positive signal for investors.<BR><BR>Investor participation has increased, with a delivery volume of 4.54 lakh shares on December 3, up by 17.57% compared to the five-day average. This rise in trading activity suggests growing interest and confidence among investors.<BR><BR>In summary, the combination of strong financial results, attractive valuation, increased investor participation, and consistent returns over the past three years are key factors contributing to the rising stock price of Glenmark Pharmaceuticals Ltd.